Ravulizumab to prevent delayed graft function after kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have end-stage kidney disease and are on dialysis.
- You are waiting for a kidney from a donor whose heart stopped (DCD) or from a high-risk brain-dead donor.
- The donor must not be from certain high-risk categories (like sudden cardiac death outside hospital).
- The donor cannot have severe acute kidney injury at the time of donation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called vonoprazan fumarate can help prevent delayed kidney function after a first kidney transplant from a deceased donor. It is for people who are ready to follow standard post-transplant care.
This study looks at ways to prevent delayed graft function — when a new kidney is slow to start working after transplant. It is open to adults receiving a kidney from a living or deceased donor, and it may help your new kidney work better sooner.
This study tests a new medicine called TNX-1500 that may help prevent the body from rejecting a new kidney. It is for people who are already waiting for a kidney transplant and aims to make the transplant more successful.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
Hear when a new Delayed Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.